Oral Motesanib significantly inhibited A549 xenograft tumor growth by 45%, 84%, and 107% at twice-daily doses of 7.5 mg/kg, 25 mg/kg, and 75 mg/kg, respectively, compared with vehicle. In male nude mice bearing A375 xenografts, Motesanib administered by intraperitoneal injection markedly impeded tumor growth compared with vehicle control treatment. In Calu-6 xenografts, significant tumor growth inhibition of 66% compared with vehicle was observed only at the highest tested oral dose of 75 mg/kg twice daily for 17 days. [2,3]
Motesanib in A549 tumor xenografts
Animal study · female athymic nude mice; A549 subcutaneous tumor xenografts; 9 to 10 per treatment group [2]
Female athymic nude mice bearing A549 subcutaneous tumor xenografts received oral Motesanib twice daily for 17 days. Tumor growth was significantly inhibited by 45%, 84%, and 107% at 7.5 mg/kg, 25 mg/kg, and 75 mg/kg, respectively, compared with vehicle.
Conditions shared by the study groups
- Route
- orally
- Treatment course
- BID; for 17 days
- Vehicle
- water, pH 2.5
- Motesanib 7.5 mg/kg BID, 25 mg/kg BID, or 75 mg/kg BID
- Model: female athymic nude mice; A549 subcutaneous tumor xenografts; 9 to 10 per treatment group
Methods and source locations
Compound reported in the paper: Motesanib
The paper names Motesanib without stating the salt or form; not verified as the diphosphate form supplied as A10608. No dose conversion or lot validation.
Results > Effect of single-agent motesanib on human NSCLC tumor growth (S8, S11); Methods > Tumor xenograft models (S76, S79, S80); Figure 2 legend (S104, S105)
Tumor volume: Tumor volume; comparator: vehicle — Results > Effect of single-agent motesanib on human NSCLC tumor growth (S11); Figure 2 legend (S104)
Motesanib 7.5 mg/kg BID, 25 mg/kg BID, or 75 mg/kg BID · Results > Effect of single-agent motesanib on human NSCLC tumor growth (S11); Methods > Tumor xenograft models (S80); Figure 2 legend (S105)
Motesanib in A375 tumor xenografts
Animal study · Male nude mice were randomly divided into three groups, A375 cells (1 × 106/point) were injected subcutaneously [3]
Male nude mice bearing subcutaneous A375 xenografts received Motesanib at 7.5 mg/kg by intraperitoneal injection once per day. Treatment markedly impeded xenograft tumor growth compared with the vehicle control treatment group.
Conditions shared by the study groups
- Route
- intraperitoneal injection
- Treatment course
- once per day
- Motesanib 7.5 mg/kg
- Model: Male nude mice were randomly divided into three groups, A375 cells (1 × 106/point) were injected subcutaneously
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Motesanib; Compound label in the paper: AMG-706
The paper names Motesanib without stating the salt or form; not verified as the diphosphate form supplied as A10608. No dose conversion or lot validation.
Results > AMG 706 activates MrgprF expression, while inhibits tumor growth (S111, S117, S118, S120); Materials and methods > Animal experiments (S191)
tumor volumes: tumor volumes; comparator: vehicle control treatment group — Results > AMG 706 activates MrgprF expression, while inhibits tumor growth (S111, S120)
Motesanib 7.5 mg/kg · Results > AMG 706 activates MrgprF expression, while inhibits tumor growth (S120); Materials and methods > Animal experiments (S191)
Motesanib in Calu-6 tumor xenografts
Animal study · female CD1 nu/nu mice; Calu-6 subcutaneous tumor xenografts; 9 to 10 per treatment group [2]
Female CD1 nu/nu mice bearing Calu-6 subcutaneous tumor xenografts received oral Motesanib twice daily for 17 days. Significant tumor growth inhibition of 66% compared with vehicle was observed only at the highest tested dose of 75 mg/kg.
Conditions shared by the study groups
- Route
- orally
- Treatment course
- twice daily (BID) for 17 days
- Vehicle
- water, pH 2.5
- Motesanib 75 mg/kg
- Model: female CD1 nu/nu mice; Calu-6 subcutaneous tumor xenografts; 9 to 10 per treatment group
Methods and source locations
Compound reported in the paper: Motesanib
The paper names Motesanib without stating the salt or form; not verified as the diphosphate form supplied as A10608. No dose conversion or lot validation.
Results > Effect of single-agent motesanib on human NSCLC tumor growth (S8, S12); Methods > Tumor xenograft models (S76, S79, S80); Figure 2 legend (S104)
Tumor volume: Tumor volume; comparator: vehicle — Results > Effect of single-agent motesanib on human NSCLC tumor growth (S12); Figure 2 legend (S104)
Motesanib 75 mg/kg · Results > Effect of single-agent motesanib on human NSCLC tumor growth (S12); Methods > Tumor xenograft models (S80)